UK markets close in 4 hours 58 minutes
Money

Best UK mortgage deals of the week

Find out the latest mortgage rates and deals from HSBC, NatWest, Santander, Barclays and more.

PHAXIAM Therapeutics S.A. (0QSS.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.0200+0.0280 (+1.41%)
As of 08:00AM BST. Market open.

PHAXIAM Therapeutics S.A.

60 Avenue Rockefeller
Bâtiment Adénine
Lyon 69008
France
33 4 78 74 44 38
https://www.phaxiam.com

Sector(s)
Industry
Full-time employees68

Key executives

NameTitlePayExercisedYear born
Ms. Cindy FevreChief Scientific OfficerN/AN/AN/A
Naomi EichenbaumDirector Investor RelationsN/AN/AN/A
Ms. Anne-Cécile FumeyVice President of Human ResourcesN/AN/A1976
Ms. Karine Charton Ph.D.Chief Business OfficerN/AN/AN/A
Dr. Pascal Birman M.D.Chief Medical OfficerN/AN/AN/A
Ms. Frederique VievilleChief Regulatory OfficerN/AN/AN/A
Dr. Philip L. Lorenzi M.D., Ph.D.Consultant & Member of Scientific BoardN/AN/AN/A
Prof. Eric Raymond M.D., Ph.D.Consultant & Member of Scientific BoardN/AN/AN/A
Dr. Bridget Bax Ph.D.Consultant & Member of Scientific BoardN/AN/AN/A
Prof. Arthur E. Frankel M.D., Ph.D.Consultant & Member of Scientific BoardN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Corporate governance

PHAXIAM Therapeutics S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.